First-in-Human Single and Multiple Dose of HL-400

PHASE1RecruitingINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

April 25, 2025

Primary Completion Date

January 30, 2026

Study Completion Date

February 27, 2026

Conditions
Parkinson Disease
Interventions
DRUG

HL-400

Part 1:Experimental: Single oral dose of HL-400, Single ascending doses, sequential assignment group design; Part 2: Experimental: Multiple oral doses of HL-400, Multiple ascending doses, QD for 14 days, sequential assignment group design; Part 3: Experimental: Multiple oral doses of HL-400, QD for 5 days.

DRUG

Placebo

Part 1: Placebo comparator: Single oral dose of placebo, single doses, matching placebo; Part 2: Placebo comparator: Multiple oral doses of placebo, multiple ascending doses, QD for 14 days, matching placebo.

Trial Locations (1)

21201

RECRUITING

Pharmaron CPC, Inc., Baltimore

All Listed Sponsors
lead

Highlightll Pharmaceutical (USA) LLC

INDUSTRY